Baby tamoxifen shows promise in preventing breast cancer recurrence

NCT ID NCT06982313

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows up on women who took a low dose of tamoxifen (5 mg daily) for three years to see if it continues to prevent breast cancer over the long term. The original trial found a 42% reduction in breast cancer events. Researchers will also combine data from three similar studies to get stronger evidence. The goal is to confirm that low-dose tamoxifen is a safe and effective prevention option for women with high-risk breast lesions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tamoxifen (low-dose, 5 mg daily)

What this could lead to

If successful, this could confirm that a low dose of tamoxifen is a safe and effective way to prevent breast cancer in women with high-risk breast changes.

What could go wrong

This is a follow-up study, not a new treatment test. The results may not apply to all women, and long-term side effects are still being monitored.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER INVASIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma breast intraductal proliferative lesion breast neoplasm ductal breast carcinoma in situ lobular breast carcinoma in situ precancerous condition invasive breast carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Study site

    Genova, Italy, 16145, Italy

  • E. O. Ospedali Galliera

    Genoa, Italy